Aidence vs Qure.ai

Qure.ai has a disclosed valuation of $270M, while Aidence's valuation is not publicly available, making a direct size comparison difficult. Qure.ai employs 250 people.

Qure.ai has raised more in total funding at $157M, compared to Aidence's $20M — a gap of $137M. Combined, the two companies have completed 5 known funding rounds.

Qure.ai holds the higher Awaira Score at 70/100, compared to Aidence's 45/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 25-point gap that reflects meaningful differences in scale or traction.

Aidence was founded by Jeroen Vendrig in 2016. Qure.ai was founded by Prashant Warier in 2016. Visit each company's profile on Awaira for a full founder biography.

Aidence: Aidence develops AI radiology software for lung cancer detection, building CE-marked and FDA-cleared deep learning algorithms that analyse CT scan images to identify and characterise pulmonary nodules requiring clinical follow-up. The Amsterdam company tools assist radiologists in national lung cancer screening programmes and in routine clinical CT reading, providing AI-generated nodule measurements, growth tracking, and malignancy risk scores that reduce reader variability and improve early detection rates.\n\nThe company raised approximately $20 million in venture funding and has deployed its Veye Chest algorithm across multiple European radiology networks and hospital systems participating in national lung cancer screening initiatives. Aidence received CE marking for its software as a medical device and has published clinical validation studies demonstrating performance that is non-inferior to specialist radiologist reads on lung nodule detection tasks.\n\nAidence competes in the AI radiology market alongside Annalise AI, Enlitic, Behold.ai, and Lunit, all of which target chest X-ray and CT reading assistance. The lung cancer screening market has expanded significantly as multiple European countries and the United States have implemented or planned national screening programmes for high-risk smokers, creating a growing workflow automation opportunity for AI lung nodule detection tools. The company was acquired by Coreline Soft, a South Korean medical AI company, as part of a broader consolidation in the AI radiology market. Qure.ai: Qure.ai is an Indian artificial intelligence company founded in 2016 that develops machine learning solutions for diagnostic imaging in healthcare. The company specializes in computer-aided detection and diagnosis systems that analyze medical imaging data including chest X-rays, CT scans, and mammograms to identify abnormalities and assist radiologists in clinical decision-making. Its platform uses deep learning algorithms trained on large datasets to detect conditions such as tuberculosis, COVID-19, lung cancer, and other pathologies. Qure.ai's products are deployed across hospitals and diagnostic centers in India and internationally, serving both institutional healthcare providers and diagnostic chains. The company has secured $157 million in total funding and operates at Series D stage with a valuation of $300 million as of recent rounds. Its technology addresses the shortage of radiologists in developing markets while improving diagnostic accuracy and turnaround times. Qure.ai competes in the medical AI space alongside companies like IBM Watson Health, Zebra Medical Vision, and various regional diagnostic AI providers. The company has demonstrated strong traction in the Indian healthcare market and has expanded its reach to international markets. Its growth trajectory reflects increasing adoption of AI-assisted diagnostic solutions globally and the rising demand for scalable healthcare technologies in resource-constrained settings. Qure.ai focuses specifically on diagnostic imaging AI for markets with radiologist shortages, positioning it distinctly within underserved geographies.

Both Aidence and Qure.ai were founded in the same year — 2016. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Aidence has approximately 1-50 employees, while Qure.ai has approximately 250. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Aidence and Qure.ai are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.